Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma
A Randomized Cross-over Phase 2 Study of the Safety and Efficacy of Two Dose Levels of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  11/20/2017
Kaiser Permanente Northwest Region Oncology Hematology
mi
from
Portland, OR
Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma
A Randomized Cross-over Phase 2 Study of the Safety and Efficacy of Two Dose Levels of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 11/20/2017
Kaiser Permanente Northwest Region Oncology Hematology
mi
from
Portland, OR
Click here to add this to my saved trials
Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma
A Randomized Cross-over Phase 2 Study of the Safety and Efficacy of Two Dose Levels of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  11/20/2017
Northwest Cancer Specialists, Pc
mi
from
Portland, OR
Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma
A Randomized Cross-over Phase 2 Study of the Safety and Efficacy of Two Dose Levels of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 11/20/2017
Northwest Cancer Specialists, Pc
mi
from
Portland, OR
Click here to add this to my saved trials
Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma
A Randomized Cross-over Phase 2 Study of the Safety and Efficacy of Two Dose Levels of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  11/20/2017
Allegheny General Hospital
mi
from
Pittsburgh, PA
Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma
A Randomized Cross-over Phase 2 Study of the Safety and Efficacy of Two Dose Levels of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 11/20/2017
Allegheny General Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma
A Randomized Cross-over Phase 2 Study of the Safety and Efficacy of Two Dose Levels of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  11/20/2017
Institute for Translational Oncology Research (ITOR)
mi
from
Greenville, SC
Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma
A Randomized Cross-over Phase 2 Study of the Safety and Efficacy of Two Dose Levels of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 11/20/2017
Institute for Translational Oncology Research (ITOR)
mi
from
Greenville, SC
Click here to add this to my saved trials
Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma
A Randomized Cross-over Phase 2 Study of the Safety and Efficacy of Two Dose Levels of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  11/20/2017
Texas Oncology-Dallas Presbyterian Hospital
mi
from
Dallas, TX
Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma
A Randomized Cross-over Phase 2 Study of the Safety and Efficacy of Two Dose Levels of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 11/20/2017
Texas Oncology-Dallas Presbyterian Hospital
mi
from
Dallas, TX
Click here to add this to my saved trials
Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma
A Randomized Cross-over Phase 2 Study of the Safety and Efficacy of Two Dose Levels of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  11/20/2017
UT Southwestern Medical Center
mi
from
Dallas, TX
Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma
A Randomized Cross-over Phase 2 Study of the Safety and Efficacy of Two Dose Levels of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 11/20/2017
UT Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma
A Randomized Cross-over Phase 2 Study of the Safety and Efficacy of Two Dose Levels of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  11/20/2017
Texas Oncology- Fort Worth - 12th Avenue
mi
from
Fort Worth, TX
Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma
A Randomized Cross-over Phase 2 Study of the Safety and Efficacy of Two Dose Levels of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 11/20/2017
Texas Oncology- Fort Worth - 12th Avenue
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma
A Randomized Cross-over Phase 2 Study of the Safety and Efficacy of Two Dose Levels of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  11/20/2017
Texas Oncology Seton Williamson
mi
from
Round Rock, TX
Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma
A Randomized Cross-over Phase 2 Study of the Safety and Efficacy of Two Dose Levels of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 11/20/2017
Texas Oncology Seton Williamson
mi
from
Round Rock, TX
Click here to add this to my saved trials
Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma
A Randomized Cross-over Phase 2 Study of the Safety and Efficacy of Two Dose Levels of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  11/20/2017
Texas Oncology - Sherman
mi
from
Sherman, TX
Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma
A Randomized Cross-over Phase 2 Study of the Safety and Efficacy of Two Dose Levels of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 11/20/2017
Texas Oncology - Sherman
mi
from
Sherman, TX
Click here to add this to my saved trials
Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma
A Randomized Cross-over Phase 2 Study of the Safety and Efficacy of Two Dose Levels of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  11/20/2017
Providence Everett Regional Medical Center, Cancer Research Dept.
mi
from
Everett, WA
Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma
A Randomized Cross-over Phase 2 Study of the Safety and Efficacy of Two Dose Levels of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 11/20/2017
Providence Everett Regional Medical Center, Cancer Research Dept.
mi
from
Everett, WA
Click here to add this to my saved trials
Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma
A Randomized Cross-over Phase 2 Study of the Safety and Efficacy of Two Dose Levels of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  11/20/2017
Columbia Basin Hematology and Oncology0
mi
from
Kennewick, WA
Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma
A Randomized Cross-over Phase 2 Study of the Safety and Efficacy of Two Dose Levels of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 11/20/2017
Columbia Basin Hematology and Oncology0
mi
from
Kennewick, WA
Click here to add this to my saved trials
Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma
A Randomized Cross-over Phase 2 Study of the Safety and Efficacy of Two Dose Levels of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  11/20/2017
University of Wisconsin
mi
from
Madison, WI
Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma
A Randomized Cross-over Phase 2 Study of the Safety and Efficacy of Two Dose Levels of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 11/20/2017
University of Wisconsin
mi
from
Madison, WI
Click here to add this to my saved trials
Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma
A Randomized Cross-over Phase 2 Study of the Safety and Efficacy of Two Dose Levels of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  11/20/2017
Cancer Care of Western North Carolina
mi
from
Asheville, NC
Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma
A Randomized Cross-over Phase 2 Study of the Safety and Efficacy of Two Dose Levels of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 11/20/2017
Cancer Care of Western North Carolina
mi
from
Asheville, NC
Click here to add this to my saved trials
Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma
A Randomized Cross-over Phase 2 Study of the Safety and Efficacy of Two Dose Levels of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  11/20/2017
Texas Oncology Wichita Falls Texoma Cancer Center
mi
from
Wichita Falls, TX
Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma
A Randomized Cross-over Phase 2 Study of the Safety and Efficacy of Two Dose Levels of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 11/20/2017
Texas Oncology Wichita Falls Texoma Cancer Center
mi
from
Wichita Falls, TX
Click here to add this to my saved trials
Phase II Gemcitabine + Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma
Phase II Multi-Institutional Study to Evaluate the Efficacy of Gemcitabine and Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  11/20/2017
Stanford University School of Medicine
mi
from
Stanford, CA
Phase II Gemcitabine + Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma
Phase II Multi-Institutional Study to Evaluate the Efficacy of Gemcitabine and Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 11/20/2017
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Phase II Gemcitabine + Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma
Phase II Multi-Institutional Study to Evaluate the Efficacy of Gemcitabine and Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  11/20/2017
Johns Hopkins Hospital
mi
from
Baltimore, MD
Phase II Gemcitabine + Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma
Phase II Multi-Institutional Study to Evaluate the Efficacy of Gemcitabine and Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 11/20/2017
Johns Hopkins Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
Phase II Gemcitabine + Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma
Phase II Multi-Institutional Study to Evaluate the Efficacy of Gemcitabine and Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  11/20/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Phase II Gemcitabine + Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma
Phase II Multi-Institutional Study to Evaluate the Efficacy of Gemcitabine and Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 11/20/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer
A Phase I Study of Veliparib (ABT-888) in Combination With Low-Dose Fractionated Whole Abdominal Radiation Therapy (LDFWAR) in Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis With Two Additional Dose Levels in Patients With Epithelial Ovarian, Fallopian or Primary Peritoneal Cancers and Intra-Abdominal Disease
Status: Enrolling
Updated:  11/20/2017
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer
A Phase I Study of Veliparib (ABT-888) in Combination With Low-Dose Fractionated Whole Abdominal Radiation Therapy (LDFWAR) in Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis With Two Additional Dose Levels in Patients With Epithelial Ovarian, Fallopian or Primary Peritoneal Cancers and Intra-Abdominal Disease
Status: Enrolling
Updated: 11/20/2017
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer
A Phase I Study of Veliparib (ABT-888) in Combination With Low-Dose Fractionated Whole Abdominal Radiation Therapy (LDFWAR) in Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis With Two Additional Dose Levels in Patients With Epithelial Ovarian, Fallopian or Primary Peritoneal Cancers and Intra-Abdominal Disease
Status: Enrolling
Updated:  11/20/2017
Johns Hopkins University-Sidney Kimmel Cancer Center
mi
from
Baltimore, MD
Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer
A Phase I Study of Veliparib (ABT-888) in Combination With Low-Dose Fractionated Whole Abdominal Radiation Therapy (LDFWAR) in Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis With Two Additional Dose Levels in Patients With Epithelial Ovarian, Fallopian or Primary Peritoneal Cancers and Intra-Abdominal Disease
Status: Enrolling
Updated: 11/20/2017
Johns Hopkins University-Sidney Kimmel Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer
A Phase I Study of Veliparib (ABT-888) in Combination With Low-Dose Fractionated Whole Abdominal Radiation Therapy (LDFWAR) in Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis With Two Additional Dose Levels in Patients With Epithelial Ovarian, Fallopian or Primary Peritoneal Cancers and Intra-Abdominal Disease
Status: Enrolling
Updated:  11/20/2017
University Health Network-Princess Margaret Hospital
mi
from
Toronto,
Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer
A Phase I Study of Veliparib (ABT-888) in Combination With Low-Dose Fractionated Whole Abdominal Radiation Therapy (LDFWAR) in Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis With Two Additional Dose Levels in Patients With Epithelial Ovarian, Fallopian or Primary Peritoneal Cancers and Intra-Abdominal Disease
Status: Enrolling
Updated: 11/20/2017
University Health Network-Princess Margaret Hospital
mi
from
Toronto,
Click here to add this to my saved trials
Study of Chemotherapy Prior to Radiotherapy and Chemotherapy in Patients With HPV Associated Cancer of the Oral Cavity
Phase II Trial of Neoadjuvant Chemotherapy for HPV-Associated Squamous Cell Carcinoma of the Oropharynx Followed by Reduced Dose Radiotherapy/Chemoradiotherapy for Responders or Standard Dose Chemoradiotherapy for Non-Responders
Status: Enrolling
Updated:  11/20/2017
Long Island Jewish Medical Center
mi
from
New Hyde Park, NY
Study of Chemotherapy Prior to Radiotherapy and Chemotherapy in Patients With HPV Associated Cancer of the Oral Cavity
Phase II Trial of Neoadjuvant Chemotherapy for HPV-Associated Squamous Cell Carcinoma of the Oropharynx Followed by Reduced Dose Radiotherapy/Chemoradiotherapy for Responders or Standard Dose Chemoradiotherapy for Non-Responders
Status: Enrolling
Updated: 11/20/2017
Long Island Jewish Medical Center
mi
from
New Hyde Park, NY
Click here to add this to my saved trials
Zoledronate in Treating Patients With Cervical Intraepithelial Neoplasia 2/3 or 3
An Exploratory Clinical Trial of Zoledronic Acid in Women With CIN 2/3 or 3
Status: Enrolling
Updated:  11/21/2017
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Zoledronate in Treating Patients With Cervical Intraepithelial Neoplasia 2/3 or 3
An Exploratory Clinical Trial of Zoledronic Acid in Women With CIN 2/3 or 3
Status: Enrolling
Updated: 11/21/2017
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer
Effects of Chemotherapy on Brain Structure and Function
Status: Enrolling
Updated:  11/21/2017
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer
Effects of Chemotherapy on Brain Structure and Function
Status: Enrolling
Updated: 11/21/2017
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Safety Study of X-82 in Patients With Advanced Solid Tumors
Phase I, First in Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of X-82 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  11/21/2017
Sarah Cannon Research Institute
mi
from
Nashville, TN
Safety Study of X-82 in Patients With Advanced Solid Tumors
Phase I, First in Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of X-82 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 11/21/2017
Sarah Cannon Research Institute
mi
from
Nashville, TN
Click here to add this to my saved trials
Study of Breast Tissue in Women Not Previously Diagnosed With Breast Cancer Who Are Undergoing Fine Needle Aspiration
Gene Methylation and Estradiol Levels in Random FNA Samples as Biomarkers for Breast Cancer Risk
Status: Enrolling
Updated:  11/21/2017
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
mi
from
Chicago, IL
Study of Breast Tissue in Women Not Previously Diagnosed With Breast Cancer Who Are Undergoing Fine Needle Aspiration
Gene Methylation and Estradiol Levels in Random FNA Samples as Biomarkers for Breast Cancer Risk
Status: Enrolling
Updated: 11/21/2017
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated:  11/21/2017
Abbott Northwestern Hospital
mi
from
Minneapolis, MN
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated: 11/21/2017
Abbott Northwestern Hospital
mi
from
Minneapolis, MN
Click here to add this to my saved trials
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated:  11/21/2017
Adena Regional Medical Center
mi
from
Chillicothe, OH
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated: 11/21/2017
Adena Regional Medical Center
mi
from
Chillicothe, OH
Click here to add this to my saved trials
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated:  11/21/2017
Alaska Regional Hospital
mi
from
Anchorage, AK
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated: 11/21/2017
Alaska Regional Hospital
mi
from
Anchorage, AK
Click here to add this to my saved trials
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated:  11/21/2017
Alegent Health Bergan Mercy Medical Center
mi
from
Omaha, NE
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated: 11/21/2017
Alegent Health Bergan Mercy Medical Center
mi
from
Omaha, NE
Click here to add this to my saved trials
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated:  11/21/2017
Alegent Health Lakeside Hospital
mi
from
Omaha, NE
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated: 11/21/2017
Alegent Health Lakeside Hospital
mi
from
Omaha, NE
Click here to add this to my saved trials
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated:  11/21/2017
Allegiance Health
mi
from
Jackson, MI
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated: 11/21/2017
Allegiance Health
mi
from
Jackson, MI
Click here to add this to my saved trials
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated:  11/21/2017
Alta Bates Summit Medical Center - Summit Campus
mi
from
Oakland, CA
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated: 11/21/2017
Alta Bates Summit Medical Center - Summit Campus
mi
from
Oakland, CA
Click here to add this to my saved trials
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated:  11/21/2017
AnMedical Health Cancer Center
mi
from
Anderson, SC
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated: 11/21/2017
AnMedical Health Cancer Center
mi
from
Anderson, SC
Click here to add this to my saved trials
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated:  11/21/2017
AnMedical Health Hospital
mi
from
Anderson, SC
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated: 11/21/2017
AnMedical Health Hospital
mi
from
Anderson, SC
Click here to add this to my saved trials
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated:  11/21/2017
Annie Penn Memorial Hospital
mi
from
Reidsville, NC
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated: 11/21/2017
Annie Penn Memorial Hospital
mi
from
Reidsville, NC
Click here to add this to my saved trials
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated:  11/21/2017
Associates in Women's Health
mi
from
Wichita, KA
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated: 11/21/2017
Associates in Women's Health
mi
from
Wichita, KA
Click here to add this to my saved trials
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated:  11/21/2017
Baptist Health Lexington
mi
from
Lexington, KY
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated: 11/21/2017
Baptist Health Lexington
mi
from
Lexington, KY
Click here to add this to my saved trials
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated:  11/21/2017
Baylor University Medical Center
mi
from
Dallas, TX
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated: 11/21/2017
Baylor University Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated:  11/21/2017
Benefis Healthcare- Sletten Cancer Institute
mi
from
Great Falls, MT
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated: 11/21/2017
Benefis Healthcare- Sletten Cancer Institute
mi
from
Great Falls, MT
Click here to add this to my saved trials
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated:  11/21/2017
Borgess Medical Center
mi
from
Kalamazoo, MI
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated: 11/21/2017
Borgess Medical Center
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated:  11/21/2017
Botsford General Hospital
mi
from
Farmington, MI
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated: 11/21/2017
Botsford General Hospital
mi
from
Farmington, MI
Click here to add this to my saved trials
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated:  11/21/2017
Boulder Community Hospital
mi
from
Boulder, CO
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated: 11/21/2017
Boulder Community Hospital
mi
from
Boulder, CO
Click here to add this to my saved trials
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated:  11/21/2017
Bozeman Deaconess Hospital
mi
from
Bozeman, MT
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated: 11/21/2017
Bozeman Deaconess Hospital
mi
from
Bozeman, MT
Click here to add this to my saved trials
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated:  11/21/2017
Bronson Methodist Hospital
mi
from
Kalamazoo, MI
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated: 11/21/2017
Bronson Methodist Hospital
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated:  11/21/2017
Cancer Care Partners, LLC
mi
from
Mishawaka, IN
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated: 11/21/2017
Cancer Care Partners, LLC
mi
from
Mishawaka, IN
Click here to add this to my saved trials
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated:  11/21/2017
Cancer Center of Kansas, PA - Chanute
mi
from
Chanute, KA
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated: 11/21/2017
Cancer Center of Kansas, PA - Chanute
mi
from
Chanute, KA
Click here to add this to my saved trials
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated:  11/21/2017
Cancer Center of Kansas, PA - Dodge City
mi
from
Dodge City, KA
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated: 11/21/2017
Cancer Center of Kansas, PA - Dodge City
mi
from
Dodge City, KA
Click here to add this to my saved trials
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated:  11/21/2017
Cancer Center of Kansas, PA - El Dorado
mi
from
El Dorado, KA
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated: 11/21/2017
Cancer Center of Kansas, PA - El Dorado
mi
from
El Dorado, KA
Click here to add this to my saved trials
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated:  11/21/2017
Cancer Center of Kansas - Fort Scott
mi
from
Fort Scott, KA
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated: 11/21/2017
Cancer Center of Kansas - Fort Scott
mi
from
Fort Scott, KA
Click here to add this to my saved trials
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated:  11/21/2017
Cancer Center of Kansas, PA - McPherson
mi
from
McPherson, KA
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated: 11/21/2017
Cancer Center of Kansas, PA - McPherson
mi
from
McPherson, KA
Click here to add this to my saved trials